Biogen Stock News

These stocks are full of growth potential.

Broadly speaking, the healthcare sector's returns in 2022 are middling. In theory, that shouldn't be the case because the group usually isn't vulnerable to two of the scenarios plaguing markets today:

Biogen Inc. (BIIB) closed the most recent trading day at $211.64, moving +0.47% from the previous trading session.

Generic sales hit MS franchise and Alzheimer's treatment is slow starter: EPS forecasts down 20%

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.

Biogen Inc. BIIB, +1.54% said Wednesday it submitted the study protocol to the Food and Drug Administration for a confirmatory clinical trial for Aduhelm, its Alzheimer's disease drug. The regulator a

Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance

Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx) for C9orf72-associated amyotrophic lateral scl

Shares of Voyager Therapeutics Inc. VYGR, +7.45% gained 2.9% in premarket trading on Tuesday after the gene therapy company said it hired former Biogen Inc. BIIB, -0.84% executive Dr. Alfred Sandrock

Scientists are criticizing the publication of results from late-stage trials of Aduhelm in a small and relatively unknown journal.

A divided U.S. appeals court on Wednesday rejected a request by Biogen Inc to reconsider a decision knocking out part of a key patent for Biogen''s multiple sclerosis drug Tecfidera.

UBS is maintaining its buy rating on Biogen (BIIB) despite Tuesday announcement the biotech is taking sole commercial rights to Alzheimers treatment Aduhelm (aducanumab) from Eisai.

Biogen Inc (NASDAQ: BIIB ) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer''s disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer''s disease pathologies, amyloid-beta plaques, and plasma p-tau181. The data also show … Full story available on Benzinga.com

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB ) announced that The Journal of Prevention of Alzheimer''s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer''s disease. The publication includes results from the primary, secondary and tertiary endpoints in the trials, as well as safety data and biomarker sub-studies. In June 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM as the first Alzheimer''s disease treatment to address a defining pathology of the disease. ADUHELM is indicated for the treatment of Alzheimer''s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.